NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NASDAQ NURO opened at $3.97 on Tuesday. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73. The business has a fifty day moving average price of $3.97 and a 200 day moving average price of $3.85. The stock has a market capitalization of $8.11 million, a P/E ratio of -0.86 and a beta of 2.20.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The firm had revenue of $0.59 million for the quarter. During the same period last year, the firm posted ($1.66) earnings per share.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.